Curaleaf's Hostile Takeover Bid for Aurora Cannabis Sparks Debate
Curaleaf Holdings has launched a hostile takeover bid for Aurora Cannabis by approaching shareholders directly after the latter rejected an initial acquisition offer. Curaleaf is offering $4 per share, representing a 45% premium over Aurora’s pre-announcement volume-weighted average price. The deal structure includes 0.3463 of a Curaleaf share plus $0.75 in cash for each Aurora share. Aurora has transformed significantly from its early days as one of the most troubled cannabis stocks, now generating strong revenue growth and operating with an improved balance sheet. In fiscal 2026, it reported net revenue of $231.3 million, a 11% increase year-over-year, driven largely by medical cannabis sales in Canada and international markets like Germany. Curaleaf sees strategic value in Aurora’s global footprint and European operations, particularly as regulatory changes have made Germany an important market for medical cannabis. The outcome of the takeover bid remains uncertain but has already caused a rise in Aurora's stock price following Curaleaf’s initial proposal.
Topics: acquisition Aurora Cannabis cannabis industry Curaleaf Holdings